Nerviplex forte
Product Description
Rhei Life d.o.o
-
Country/Region:Serbia
-
On CPHI since:2023
-
Certificates:3
-
Employees:25 - 49
Company types
Primary activities
Categories
Specifications
Rhei Life d.o.o
-
Country/Region:Serbia
-
On CPHI since:2023
-
Certificates:3
-
Employees:25 - 49
Company types
Primary activities
More Products from Rhei Life d.o.o (2)
-
Product Rheial intra-articular injections
Rheial offers a wide range of HA concentrations and volumes for all types of joints and patients. • Linear Hyaluronic acid • Cross-linked Hyaluronic acid HA (hyaluronic acid) • 20 mg/2 ml • 32 mg/2 ml • 40 mg/2 ml • 48 mg/2 ml • 60 mg/2 ml • 60 mg/3 ml ... -
Product Nerviplex
Nerviplex is nucleotide based food supplements, with high concentration of nucleotides of pyrimidine bases and vitamins indicated for treatment of peripheral neuropathies. Nucleotides act directly by regenerating damaged nerves, improving myelin sheath regeneration, increasing motor neuron conduction and a...
Rhei Life d.o.o resources (2)
-
Industry Webinar ENCACTUS Study: A New Chapter in Nucleotide Therapy for Neuropathy
This session presents primary data from the ENCACTUS clinical trial, an independent, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Nerviplex, a nucleotide-based formulation, in the treatment of carpal tunnel syndrome. Emphasis will be placed on clinical endpoints, study design, and translational potential in the context of compressive neuropathies.
Key discussion points: Study rationale and methodology of the ENCACTUS trial Efficacy outcomes and safety profile of Nerviplex vs. placebo Role of nucleotide-based therapy in peripheral nerve regeneration Clinical implications for underdiagnosed neuropathic conditions Comparison with standard over-the-counter interventions -
.png)
Video Navigating Neuropathy: Key Discoveries From Nerviplex Clinical Trials
Gain new insights into nucleotides through groundbreaking clinical trials conducted on Nerviplex and Nerviplex Forte, two pharmaceutical formulations designed to address peripheral neuropathies. These placebo-controlled, double-blind studies adhere to rigorous drug-like protocols, ensuring robust results in both efficacy and safety. Focused on carpal tunnel syndrome and diabetic polyneuropathy, our research aims to illuminate the innovative mechanisms of action behind nucleotide therapy and how these formulations deliver tangible outcomes. Attendees will gain valuable insights into the transformative potential of these treatments in neuropathy management.